Abstracts Archive - Page 220 of 2425 - ACR Meeting Abstracts

Abstract Number: 0824 • ACR Convergence 2023
Defining Poor Global Functioning and Health in Axial Spondyloarthritis, Using the EQ-5D-3L Questionnaire, When the ASAS-Health Index Is Not Available Is Feasible. an Analysis of 2651 Patients from the PERSPA Study
Juliette Drouet¹, Clementina López Medina², Anna Molto³, Benjamin Granger¹, Bruno Fautrel⁴, Cécile Gaujoux Viala⁵, Uta Kiltz⁶, Maxime Dougados⁷ and Laure Gossec⁸, ¹Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Sorbonne Université APHP, Paris, France, ⁵IDESP Univ Montpellier, INSERM, Rheumatology, CHU Nîmes, Montpellier, France, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ⁸Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: In axial Spondyloarthritis (axSpA) it is recommended to assess global functioning and health, a concept close to health-related quality of life (HR-QoL), using the…
Abstract Number: 0543 • ACR Convergence 2023
Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015
Hilde Haukeland¹, Sigrid Reppe Moe¹, Cathrine Brunborg², Antonela Botea³, Nenad Damjanic⁴, Gro Wivestad⁵, Heidi Øvreås⁶, Thea Bøe⁷, Torhild Garen¹, Anniken Orre⁸, Helga Sanner⁹, Øyvind Molberg¹⁰ and Karoline Lerang⁹, ¹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ³Betanien Hospital, Department of Rheumatology, Skien, Norway, ⁴Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, ⁵Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, ⁷Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, ⁸Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, ⁹Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, ¹⁰University of Oslo, Institute of Clinical Medicine, Oslo, Norway
Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
Abstract Number: 0826 • ACR Convergence 2023
Development of a Decision Aid for Clinical Trial Participation in Systemic Lupus Erythematosus
Leila Khalili¹, Rita Kukafka², Laura Geraldino-Pardilla¹, Nancyanne Schmidt¹, Sean Inzerillo¹, Julia Weiner¹, Wei Tang¹ and Anca Askanase³, ¹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ²Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, ³Columbia University Medical Center, New York, NY
Background/Purpose: Standard of care therapy for SLE relies heavily on broad-spectrum immune suppressants. Therapeutic drug development is critical to the approval of targeted therapies; however,…
Abstract Number: 0785 • ACR Convergence 2023
Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie M. Bartels³, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of lupus (or SLE) treatment. Yet the optimal dosing of HCQ in SLE is unknown. Reducing HCQ dose to…
Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Caleb Bolden¹, Claire Cook¹, Lucy Finkelstein-Fox¹, Xiaoqing Fu¹, Flavia Castelino¹, Hyon K. Choi², Cory Perugino¹, John Stone³, Elyse Park¹, Zachary Wallace⁴ and Daniel Hall¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…
Abstract Number: 0469 • ACR Convergence 2023
Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network
Julia Simard¹, Emily Liu², Amadeia Rector³, Miranda Cantu⁴, Daniel Kuo⁵, Eliza Chakravarty⁶, Maurice Druzin⁷, Gary Shaw⁷, Michael Weisman⁸ and Monique Hedderson², ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Stanford University, San Francisco, CA, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Stanford University, Stanford, CA, ⁸Stanford, Los Angeles, CA
Background/Purpose: Pregnancies in patients with systemic lupus erythematosus (SLE) are at greater risk of preeclampsia. Hydroxychloroquine (HCQ) is recommended during SLE pregnancy to control disease…
Abstract Number: 0768 • ACR Convergence 2023
Using Participatory Design-Thinking Process to Create a More Applicant-Centered Rheumatology Fellowship Interview Experience
Alick Feng, Ayesha Iftekhar, Ruoning Ni, Gatra Gheriani and Bharat Kumar, University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Design-thinking is a creative problem-solving process used to better understand users’ needs and experiences so that a product or service can be improved. Its…
Abstract Number: 0705 • ACR Convergence 2023
Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc)
Misa Tanaka¹, Saverio Stranges¹, Kathy Speechley¹, Osvaldo Espin Garcia¹, Molly Mason², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Indira Gurubhagavatula⁴, Christian Pagnoux⁵, Peter Merkel⁴ and Lillian Barra¹, ¹Western University, London, ON, Canada, ²Vasculitis Patient Powered Research Network, Philadelphia, PA, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Sleep deprivation and sleep disorders can impair health-related quality of life and increase the risk of chronic diseases, such as cardiovascular disease, and mental…
Abstract Number: 0819 • ACR Convergence 2023
Regression to the Mean for Physical Function and Quality of Life in Trials for Symptomatic Knee Osteoarthritis
Martin Englund and Aleksandra Turkiewicz, Lund University, Lund, Sweden
Background/Purpose: Improvement in pain reported in clinical trials for osteoarthritis (OA) is typically strongly depending on the regression-to-the-mean phenomenon. Regression to the mean has been…
Abstract Number: 0792 • ACR Convergence 2023
Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease
Richard Ainsworth¹, Kim Taylor², Ye Cao³, Takanori Sasaki⁴, Deepak Rao⁵, Nunzio Bottini⁶ and Francesco Boin¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Francisco, San Francisco, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶University of California, San Francisco, CA
Background/Purpose: Growing evidence supports a critical role for innate immunity in systemic sclerosis (SSc) pathogenesis. Altered myeloid cell numbers and functions have been implicated in…
Abstract Number: 0353 • ACR Convergence 2023
Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods
Patricia Hoffman¹, Lauren Parlett², Daniel Beachler², Daniel Reiff³, Sarah McGuire¹, Sonia Pothraj¹, Lakshmi Moorthy¹, Cynthia Salvant⁴, Dawn Koffman⁵, Sanika Rege⁵, Cecilia Huang⁵, Matthew Iozzio⁵, Kevin Schott², Kevin Haynes⁶, Amy Davidow⁷, Stephen Crystal⁸, Tobias Gerhard⁵, Brian Strom⁹, Carlos Rose¹⁰ and Daniel Horton⁴, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Carelon, Wilmington, DE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁶Janssen Pharmaceuticals, Raritan, NJ, ⁷New York University, New York, NY, ⁸Rutgers University, New Brunswick, NJ, ⁹Rutgers, State University of New Jersey, New Brunswick, NJ, ¹⁰Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Administrative claims databases represent important settings for studying large populations with juvenile idiopathic arthritis (JIA), but prior efforts to validate diagnostic algorithms for JIA…
Abstract Number: 0721 • ACR Convergence 2023
Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica
Tonya K Marmon¹, Jason C Cole², Claire Owen³, Sarah Mackie⁴ and David Katz⁵, ¹Marmon Biostatistics, Seattle, WA, ²P3 Research Consulting, Torrance, CA, ³Austin Health, Malvern East, Australia, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
Abstract Number: 0731 • ACR Convergence 2023
ZEB2 Acts as a Crucial Transcriptional Regulator Governing Age-Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus
Dai Dai¹, Shuangshuang Gu¹, Xiaxia Han¹, Huihua Ding², Yang Jiang¹, Sheng Chen¹ and Nan Shen², ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Age-associated B cells (ABCs) accumulate and contribute to the pathogenesis of systemic autoimmune diseases like lupus. Despite recent insights into the ontogeny and function…
Abstract Number: 0820 • ACR Convergence 2023
Radiographic and Pain Outcomes from a Phase 3 Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Severe Osteoarthritis of the Knee (OA-07): 36 Month Single Blind and Placebo Crossover Phase Results
Yusuf Yazici¹, Christopher Swearingen², Victor Lopez³, Jon Britt⁴, Sarah Kennedy⁵, Jeyanesh Tambiah² and Timothy McAlindon⁶, ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics, Inc., San Diego, CA, ³Biosplice Therapeutics, Inc., Santa Clarita, CA, ⁴Biosplice Therapeutics, Inc., Los Angeles, CA, ⁵Biosplice Therapeutics, Inc., Superior, CO, ⁶Tufts Medical Center, Arlington, MA
Background/Purpose: Knee osteoarthritis (OA) has unmet need for safe, efficacious symptom and disease-modifying treatments. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate Wnt…
Abstract Number: 0487 • ACR Convergence 2023
A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
Ashmia Saif¹, Priyanka Dongare², Meghan Beard³, Yunhan Liao⁴, Xiaoyue Zhang⁴, Qingping Yao⁵ and Asha Patnaik⁶, ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University Hospital, Highland, NY, ³Stony Brook Southampton, Moriches, NY, ⁴Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ⁵Stony Brook University, Stony Brook, NY, ⁶Stony Brook University Medical Center, East Setauket, NY
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].